Scary IPAF IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7

Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications? This is the https://t.co/WVSjwIHOAM

Might stem cells actually work in knee OA?? Possibly, only the right combo 🇰🇷 OSCA: OS (allo mesenchymal stem cells) + CAM (cartilage acellular matrix) anti-inflamm, structural, pain ph2a impressive signal over placebo & maybe tissue repair, benefit out to 5y? #ACR26 @RheumNow https://t.co/PU3MUqxH7Q

It's like HCQ on steroids (metaphorical not literal, & anabolic not glucocorticoid) TLR7/8 targeting in SLE (IFN-I, GC resistance, organ damage) ph2: massive signal in primary, secondaries all hit, IFN-I down from w2, safety good what a time for lupus ABSTLB23 #ACR26 @RheumNow https://t.co/mhntxC4aT4

Is 60-40-20 broken? RA trial rule of thumb: roughly 60%-40%-20% for ACR20-50-70 girocitinib (JAK1/Tyk2) vs tofacitinib ACR20: 91% vs 75% ACR50: 73% vs 49% ACR70: 44% vs 25% there will be debate (all in China, tofa exposure) but what a meeting for H2H ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg

Is it the treatment or the disease? -Multiple meds can cause SCLE: more widespread, EM,Bullous features. -Dupilumab can cause enthesitis: if severe needs dc of medication -Anti-CD 20 may cause IBD (Crohn’s-Like) Great lecture from @md_chawla on Drug induced syndromes #ACR26 https://t.co/EEQL7QNtWC